PEGylated palladium doped ceria oxide nanoparticles (Pd-dop-CeO 2 -PEG NPs) for inhibition of bacterial pathogens and human lung cancer cell proliferation
Journal of Drug Delivery Science and Technology, ISSN: 1773-2247, Vol: 72, Page: 103367
2022
- 9Citations
- 14Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Article Description
Antibacterial and anticancer activities of metallic nanoparticles are limited due to their instability and agglomeration. Therefore, we hypothesize that the coating of biocompatible polyethylene glycol (PEG) improves stability, prevents agglomeration, and enhance the prolongs blood circulation. Hence, this work reports the characterization, anticancer and antibacterial activities of Pd-dop-CeO 2 -PEG synthesized by Trichoderma extract (FE-En). The reduction of broad-spectrum intensity at 420 nm indicated the successful synthesis of Pd (2+) to Pd (0) NPs. The TEM results revealed that doping of CeO 2 and PEG conjugation did not affect the morphology and dispersion of Pd NPs, Pd-dop-CeO 2, and Pd-dop-CeO 2 -PEG. All three nanoparticles were polydispersed and spherical in shape. The sizes were 8.01 ± 2.46 nm for PdNPs, 9.02 ± 3.15 nm for Pd-dop-CeO 2, and 12.95 ± 3.41 nm for Pd-dop-CeO 2 -PEG. The zeta potential was −29.9 ± 0.89 mV for Pd NPs, −38.9 ± 0.15 mV for Pd–CeO 2 and - 42.2 ± 0.74 mV for Pd-dop-CeO 2 -PEG. FTIR results revealed the involvement of –OH and the amide group of FE-En in the synthesis of Pd (2+) ions to Pd (0) NPs. XRD analysis confirmed the crystalline structure of Pd NPs, Pd-dop- CeO 2, and Pd-dop-CeO 2 -PEG. The Pd-dop-CeO 2 -PEG NPs were biocompatible with chick embryos and NIH3T3 cells. However, these NPs exhibited strong cytotoxicity to A549 cells with an IC 50 of 81.25 ± 1.21 μg/mL for Pd-dop-CeO 2 -PEG, 118.75 ± 0.89 μg/mL for Pd-dop-CeO 2, and 231.25 ± 2.08 μg/mL for PdNPs. Further, fluorescent staining results confirmed that the Pd-dop-CeO 2 -PEG induced cell death in A549 cells through cellular damage by oxidative stress. Also, Pd-dop-CeO 2 -PEG exhibited higher antibacterial activity against bacterial pathogens. Overall, these results confirmed the successful development of Pd-dop-CeO 2 -PEG as a promising anticancer and antibacterial agents.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S1773224722002775; http://dx.doi.org/10.1016/j.jddst.2022.103367; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85129646909&origin=inward; https://linkinghub.elsevier.com/retrieve/pii/S1773224722002775; https://dx.doi.org/10.1016/j.jddst.2022.103367
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know